 | Up a level |
Cappellini, M. D. and Viprakasit, V. and Taher, A. T. and Georgiev, P. and Kuo, K. H. M. and Coates, T. and Voskaridou, E. and Liew, H. -K. and Pazgal-Kobrowski, I. and Forni, G. L. and Perrotta, S. and Khelif, A. and Lal, A. and Kattamis, A. and Vlachaki, E. and Origa, R. and Aydinok, Y. and Bejaoui, M. and Ho, P. J. and Chew, L. -P. and Bee, P. -C. and Lim, S. -M. and Lu, M. -Y. and Tantiworawit, A. and Ganeva, P. and Gercheva, L. and Shah, F. and Neufeld, E. J. and Thompson, A. and Laadem, A. and Shetty, J. K. and Zou, J. and Zhang, J. and Miteva, D. and Zinger, T. and Linde, P. G. and Sherman, M. L. and Hermine, O. and Porter, J. and Piga, A. and Investigators, BELIEVE (2020) A phase 3 trial of Luspatercept in patients with transfusion-dependent beta-thalassemia. New England Journal of Medicine, 382 (13). pp. 1219-1231. ISSN 0028-4793, DOI https://doi.org/10.1056/NEJMoa1910182.
